Unlike the breast cancer studies, treatment with X15695 did not strongly downregulate AR level in LNCaP prostate cancer cells nor in the castration-resistant prostate cancer (CRPC) cell line 22Rv.1 (Fig. 7C). This evidence concerns the gene AR and breast carcinoma.